EU/3/10/750: Orphan designation for the treatment of tuberculosis


Table of contents


On 9 June 2010, orphan designation (EU/3/10/750) was granted by the European Commission to Sanofi-Aventis, France, for rifapentine for the treatment of tuberculosis.

In October 2012, Sanofi-Aventis changed name to Sanofi-Aventis Groupe.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Intended use
Treatment of tuberculosis
Orphan designation status
EU designation number
Date of designation
Sanofi-Aventis Groupe
54 rue de la Boétie
75008 Paris
Tel. +33 153 774 000
Fax +33 153 774 133

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating